X
Subscription
Thank You
Thank you for your subscription
* Required fields
Life Sciences & Med Tech
company
contacts
sector
status
description

CEO: Sérgio Simões

ssimoes@bluepharma.pt

sector:

Oncology

status:
Seed
description:

Developing a photodynamic (light-based) therapy effective against primary tumors and metastasis.

CEO: Diogo Remechido Anjos

diogo.anjos@lymphact.com

sector:

Oncology

status:
Seed
description:

Developing a new technology platform, targeting cancer and chronic viral infections, called DOT cells, which do not attack healthy cells and quickly react to bad ones.

CEO: João Pereira

jpereira@magnomics.pt

sector:

Medical Devices

status:
Seed
description:

Developing nanotech-based, fully in-vitro molecular devices for point-of-care diagnosis or bacterial infections. Initial focus on the veterinary market.

CEO: Rui Oliveira

rmo@fct.unl.pt

sector:

Biotechnology

status:
Exited
description:

Focusing on Cell culture media formulation methods for the BioPharma industry to significantly enhance the yields of culture media.

CEO: João Pedro Ribeiro

joao.ribeiro@peekmed.com

sector:

Healthcare IT

status:
Seed
description:

PeekMed is a software solution developed for orthopedic surgeons, aims to optimize the pre-operative planning process. By simulating the expected results prior to the surgery occurring, it allows for more accuracy in the actual surgery.

CEO: João Barreto

jpbar@perceive3d.com

sector:

Healthcare IT

status:
Early
description:

Developing and manufacturing computer vision solutions for medical endoscopy. RDFixer is a visualisation system, the first of its kind on the market, that improves depth perception by removing the image distortion in real-time when performing Minimally Invasive Surgery.

sector:

Medical Devices

status:
Early
description:

Developing and manufacturing the next generation of silicon-based photomultipliers for Positron Emission Tomography.

CEO: Filipe Aguiar

bio73100@gmail.com

sector:

Biotechnology

status:
Exited
description:

Developing innovative functional excipients for application in the pharmaceutical and cosmetics industry, increasing efficiency, hence increasing production capacity via throughput.

Rui Amandi de Sousa

rasousa@stemmatters.com

sector:

Biotechnology

status:
Seed
description:

Develops medical devices and advanced therapies for regenerative medicine applications based on proprietary biomaterial platforms and tissue engineering.

CEO: Richard Hampson

rhampson@thelial.com

sector:

Biotechnology

status:
Exited
description:

Discovering and developing new generation drug candidates, at less than 10% of the industry's average cost. Its technological platform enables customisation to other targets related to carcinoma.